StartPRE • NASDAQ
add
Prenetics Global Ltd
4,42 $
Efter lukketid:(5,20 %)+0,23
4,65 $
Lukket: 22. nov., 20.00.00 GMT-5 · USD · NASDAQ · Ansvarsfraskrivelse
Seneste lukkekurs
4,61 $
Dagsinterval
4,42 $ - 4,42 $
Årsinterval
2,85 $ - 7,84 $
Markedsværdi
54,00 mio. USD
Gns. volumen
11,72 t
P/E-værdi
-
Udbytteprocent
-
Primær børs
NASDAQ
Markedsnyheder
Økonomi
Resultatopgørelse
Indtægt
Nettoindtægt
(USD) | jun. 2024info | År til år-ændring |
---|---|---|
Indtægt | 5,94 mio. | 4,32 % |
Driftsudgifter | 14,38 mio. | 0,52 % |
Nettoindtægt | -10,72 mio. | 50,83 % |
Overskudsgrad | -180,46 | 52,87 % |
Earnings per share | — | — |
EBITDA | -9,51 mio. | 13,59 % |
Effektiv afgiftssats | 0,79 % | — |
Årsbalance
Samlede aktiver
Samlede passiver
(USD) | jun. 2024info | År til år-ændring |
---|---|---|
Kontanter og korttidsinvesteringer | 63,89 mio. | -67,46 % |
Samlede aktiver | 233,31 mio. | -16,93 % |
Samlede passiver | 42,30 mio. | -30,22 % |
Samlet egenkapital | 191,00 mio. | — |
Shares outstanding | 12,22 mio. | — |
Kurs/indre værdi | 0,30 | — |
Afkast af aktiver | -11,12 % | — |
Afkast af kapital | -13,33 % | — |
Pengestrøm
Nettoændring i likviditet
(USD) | jun. 2024info | År til år-ændring |
---|---|---|
Nettoindtægt | -10,72 mio. | 50,83 % |
Pengestrøm fra drift | — | — |
Pengestrøm fra investering | — | — |
Pengestrøm fra finansiering | — | — |
Nettoændring i likviditet | — | — |
Fri pengestrøm | — | — |
Om
Prenetics is a health sciences company headquartered in Hong Kong with a significant presence in the United States. It is best known for its innovations in consumer and clinical health, focusing on early detection, prevention, and treatment of diseases, particularly cancer.
Prenetics' consumer initiatives are spearheaded by IM8, a health and wellness brand. Another key offering is CircleDNA, which utilizes next-generation sequencing technology to provide comprehensive DNA testing for consumers, offering insights into health, wellness, and genetic predispositions.
The company's clinical arm includes Insighta, a joint venture focused on developing multi-cancer early detection technologies. Additionally, ACT Genomics develops and provides a variety of genomic profiling panels, including ACTOnco, ACT HRD, ACTFusion, and ACTDrug tests, tailored to meet specific clinical needs. ACTLiquid Pro, a sequencing-based liquid biopsy assay, and ACTMonitor, which tracks drug resistance, treatment response, and cancer recurrence in real-time, are among its notable products. ACT Risk offers management solutions for assessing and mitigating cancer risks. Wikipedia
Grundlagt
2014
Website
Ansatte
322